Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Hims & Hers Health Inc (NY: HIMS ) 18.94 -0.37 (-1.92%) Streaming Delayed Price Updated: 11:53 AM EDT, Oct 2, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Hims & Hers Health Inc < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer Today 4:55 EDT Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. Via The Motley Fool Hims & Hers To Offer Access To Compounded Diabetes And Weight Loss Drugs For Just $99/Month To Certain Professional Personnel September 19, 2024 Hims & Hers Health will offer compounded GLP-1 weight-loss medications for as low as $99 per month to eligible U.S. military personnel, veterans, teachers, nurses, and first responders. The telehealth... Via Benzinga Hims & Hers to Offer Access to Compounded GLP-1 Injections for as Low as $99/Month to U.S. Military, Veterans, Teachers, Nurses and First Responders September 18, 2024 From Hims & Hers Via Business Wire Hims & Hers Acquisition: How Innovation Will Flourish September 18, 2024 Buying a new pharmacy will allow Hims & Hers to expand into new markets. Via The Motley Fool How Is The Market Feeling About Hims & Hers Health? September 17, 2024 Via Benzinga Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings) September 13, 2024 Via Benzinga Is Hims & Hers Health Stock a Buy? September 10, 2024 The risk-reward proposition is pretty one-sided here. Via The Motley Fool Is Hims & Hers Health Stock a Buy? August 29, 2024 The stock has been a strong performer this year, but the best could be yet to come. Via The Motley Fool 1 Telemedicine Stock I Wouldn't Touch With a 10-Foot Pole (Hint: It's Not Teladoc) September 17, 2024 Telemedicine once seemed like it was going to revolutionize healthcare. Via The Motley Fool Hims & Hers Stock Pops After Massive Acquisition September 13, 2024 The healthcare company will be making more of the product it sells. Via The Motley Fool Hims & Hers Health Stock Is Crashing: Should You Buy the Dip? September 11, 2024 Shares of Hims & Hers are falling even as the company has been posting some solid results. Via The Motley Fool Is Hims & Hers Health the Next Teladoc? September 11, 2024 Telemedicine was one of the most in-demand services during the height of the COVID-19 pandemic. Via The Motley Fool Exposures COVID-19 Novo Nordisk Reports Positive Results Of Weight-Loss Drug Liraglutide For Children As Young As 6, Eyes FDA And EMA Approval September 11, 2024 Novo Nordisk has announced that its weight-loss drug liraglutide is safe and effective for children as young as six. The company-funded study revealed a 7.4% reduction in body-mass index for children... Via Benzinga Exposures Product Safety What Is Going On With Hims & Hers Stock? August 22, 2024 After a strong start to the year, the stock is down 30% since June. Via The Motley Fool The Latest Analyst Ratings For Hims & Hers Health August 22, 2024 Via Benzinga Looking Into Hims & Hers Health's Recent Short Interest August 19, 2024 Via Benzinga Invest While You Can: Pullbacks on These 3 Stocks Won’t Last Long September 10, 2024 Three stocks stand out for investors to consider as they recently had big selloffs. There are fundamental reasons to believe that these discounts won't last Via MarketBeat Topics Economy Exposures Economy Interest Rates Four Stocks To Watch This Week - Monday, Sept 9 September 09, 2024 Inconsistent patchy behavior looks most likely in the very short term, but stocks still have decent potential in the medium term. Stay focused and be patient for the optimal setups near Key Levels. Via Talk Markets Battle Over Compounded Weight-Loss Medications - Sustainability and Regulation September 05, 2024 Explore how Hims & Hers competes with big pharma amid weight-loss drug shortages, offering cheaper alternatives and facing sustainability challenges. Via Benzinga Eli Lilly Just Made Zepbound Even More Appealing. Here's What Smart Investors Need to Know. September 05, 2024 Lilly just lowered the price of Zepbound. Via The Motley Fool Got $1,000? 3 Healthcare Stocks to Buy and Hold Forever September 05, 2024 There is something for everybody in America's $4.5 trillion healthcare market. Via The Motley Fool Billionaires Are Buying Hims & Hers Health Hand Over Fist. Should You Follow Their Lead? September 01, 2024 Sales growth could accelerate now that it provides lower-cost, weight-management drugs. Via The Motley Fool 2 No-Brainer Growth Stocks to Buy With $200 Right Now August 31, 2024 These businesses are rapidly growing profits and cash flows. Via The Motley Fool Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review August 30, 2024 The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. Via Investor's Business Daily Topics Stocks Exposures US Equities Why Hims & Hers Health Stock Was Falling This Week August 29, 2024 A new threat from Eli Lilly pushed the stock lower. Via The Motley Fool Why Hims & Hers Stock Crashed on Tuesday August 27, 2024 Could a competitor lowering prices eat into Hims & Hers market share? Via The Motley Fool Why Hims & Hers Health Stock Is Falling August 27, 2024 Eli Lilly's launch of the competitively priced Zepbound has triggered a 4.9% drop in Hims & Hers' stock. This has raised concerns over increased competition and potential market share loss. Via Benzinga American Woodmark Reports Downbeat Results, Joins Snowflake And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session August 27, 2024 Via Benzinga Eli Lilly Halves Zepbound Price In New Version Of Weight-Loss Drug August 27, 2024 The single-dose vials will also increase supply, the drug giant says. Via Investor's Business Daily Hims & Hers Health Sees Major Growth Opportunity In Booming Weight Loss Market, Says Analyst August 22, 2024 Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.